Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Veracyte, Inc. - Common Stock
(NQ:
VCYT
)
36.27
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Mar 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Veracyte, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Veracyte Completes Acquisition of C2i Genomics
February 06, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
January 08, 2024
From
Veracyte, Inc.
Via
Business Wire
Cathie Wood's Ark Invest Buys Over $92M Worth Of ProShares Bitcoin ETF, Sells Coinbase, Block And Palantir Shares
↗
December 27, 2023
On Wednesday, Cathie Wood-led Ark Invest made a significant move in the cryptocurrency space, purchasing over $92 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO).
Via
Benzinga
Topics
ETFs
Veracyte: Q3 Earnings Insights
↗
November 07, 2023
Via
Benzinga
The Latest Analyst Ratings for Veracyte
↗
October 20, 2023
Via
Benzinga
Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 12, 2023
From
Veracyte, Inc.
Via
Business Wire
Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
December 01, 2023
From
Veracyte, Inc.
Via
Business Wire
Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
November 29, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023
November 22, 2023
From
Veracyte, Inc.
Via
Business Wire
Are You A Trader Or Investor: Biotech Momentum Is Picking Up
↗
November 20, 2023
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market.
Via
Talk Markets
Topics
ETFs
Veracyte Announces Third Quarter 2023 Financial Results
November 07, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally
November 07, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in the Stephens Annual Investment Conference
November 02, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development
October 27, 2023
From
Veracyte, Inc.
Via
Business Wire
Earnings Scheduled For November 7, 2023
↗
November 07, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
Via
Benzinga
7 Undervalued Stocks That Analysts Love Right Now
↗
October 26, 2023
With many investors concerned about what may lie ahead in the market, these potentially de-risked undervalued stocks may be ideal.
Via
InvestorPlace
Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023
October 17, 2023
From
Veracyte, Inc.
Via
Business Wire
New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease
October 12, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Stock Is Volatile After-Hours - Here's Why
↗
October 04, 2023
Veracyte, Inc. (NASDAQ: VCYT) shares are volatile after-hours on Wednesday after the company announced that new data from a phase 3 trial validates the value of the Decipher Prostate Genomic Classifier...
Via
Benzinga
New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier
October 04, 2023
From
Veracyte, Inc.
Via
Business Wire
New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer
September 28, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023
September 28, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer
September 27, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting
September 21, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests
September 07, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies
September 06, 2023
From
Veracyte, Inc.
Via
Business Wire
Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors?
↗
September 02, 2023
The genetic test maker is rapidly increasing test volumes.
Via
The Motley Fool
Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
August 29, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer
August 22, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego
August 15, 2023
From
Veracyte, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
